The ABIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ABIO Detailed Price Forecast - CNN Money||View ABIO Detailed Summary - Google Finance|
|View ABIO Detailed Summary - Yahoo! Finance||View ABIO Stock Research & Analysis - Zacks.com|
|View ABIO Trends & Analysis - Trade-Ideas||View ABIO Major Holders - Barrons|
|View ABIO Call Transcripts - NASDAQ||View ABIO Breaking News & Analysis - Seeking Alpha|
|View ABIO Annual Report - CompanySpotlight.com||View ABIO OTC Short Report - OTCShortReport.com|
|View ABIO Fundamentals - TradeKing||View ABIO SEC Filings - Bar Chart|
|View Historical Prices for ABIO - The WSJ||View Performance/Total Return for ABIO - Morningstar|
|View the Analyst Estimates for ABIO - MarketWatch||View the Earnings History for ABIO - CNBC|
|View the ABIO Earnings - StockMarketWatch||View ABIO Buy or Sell Recommendations - MacroAxis|
|View the ABIO Bullish Patterns - American Bulls||View ABIO Short Pain Metrics - ShortPainBot.com|
|View ABIO Stock Mentions - StockTwits||View ABIO Stock Mentions - PennyStockTweets|
|View ABIO Stock Mentions - Twitter||View ABIO Investment Forum News - Investor Hub|
|View ABIO Stock Mentions - Yahoo! Message Board||View ABIO Stock Mentions - Seeking Alpha|
|View Insider Transactions for ABIO - SECform4.com||View Insider Transactions for ABIO - Insider Cow|
|View ABIO Major Holdings Summary - CNBC||View Insider Disclosure for ABIO - OTC Markets|
|View Insider Transactions for ABIO - Yahoo! Finance||View Institutional Holdings for ABIO - NASDAQ|
|View ABIO Stock Insight & Charts - FinViz.com||View ABIO Investment Charts - StockCharts.com|
|View ABIO Stock Overview & Charts - BarChart||View ABIO User Generated Charts - Trading View|
Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks
Posted on Tuesday June 19, 2018
Research coverage has been initiated by WallStEquities.com on Aimmune Therapeutics Inc. (NASDAQ: AIMT), Alkermes PLC (NASDAQ: ALKS), Aratana Therapeutics Inc. (NASDAQ: PETX), and ARCA biopharma Inc. (NASDAQ: ABIO). The majority of Biotech companies research and develop products for the healthcare market.
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that data from the GENETIC-AF clinical trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European Society of Cardiology Heart Failure 2018 World Congress on Sunday May 27, 2018. William T. Abraham, M.D., Professor of Medicine, Physiology and Cell Biology and Director, Division of Cardiovascular Medicine at the Ohio State University presented the data. The presentation is available at http://arcabio.com/investors/investor-presentations/. In the overall study population of heart failure patients who were at high risk for recurrent atrial fibrillation (AF), pharmacogenetic guided GencaroTM did not reduce AF/AFL/ACM recurrence compared to the active comparator TOPROL-XL.
Today’s Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma
Posted on Friday May 11, 2018
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / vTv Therapeutics and ARCA biopharma were both soaring in Thursday's trading session. Both had news as catalysts to drive shares higher with vTv Therapeutics announcing ...
ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress
Posted on Thursday May 10, 2018
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that data from the Phase 2B GENETIC-AF clinical trial has been selected for a “Late Breaking Clinical Trials” oral presentation at the European Society of Cardiology Heart Failure 2018 World Congress being held May 26-29, 2018 in Vienna, Austria. William T. Abraham, M.D., Professor of Medicine, Physiology and Cell Biology and Director, Division of Cardiovascular Medicine at the Ohio State University will present the data.